Alaethes Wealth LLC Increases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

by · The Cerbat Gem

Alaethes Wealth LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 4.8% in the first quarter, Holdings Channel.com reports. The firm owned 2,955 shares of the medical research company’s stock after purchasing an additional 134 shares during the period. Alaethes Wealth LLC’s holdings in Thermo Fisher Scientific were worth $1,472,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company’s stock valued at $16,659,627,000 after purchasing an additional 230,382 shares during the period. Amundi grew its position in shares of Thermo Fisher Scientific by 5.9% in the first quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock valued at $1,426,316,000 after purchasing an additional 168,197 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company’s stock valued at $1,455,774,000 after purchasing an additional 115,463 shares during the period. Pictet Asset Management Holding SA grew its position in shares of Thermo Fisher Scientific by 7.2% in the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company’s stock valued at $1,432,816,000 after purchasing an additional 193,378 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock worth $1,368,859,000 after buying an additional 329,974 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TMO. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They issued an “outperform” rating on the stock. Barclays lifted their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an “equal weight” rating in a report on Thursday, July 24th. UBS Group lifted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Finally, Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $589.38.

Get Our Latest Stock Analysis on Thermo Fisher Scientific

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares of the company’s stock, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,666 shares of company stock worth $13,982,763 over the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.1%

NYSE:TMO opened at $487.11 on Tuesday. The business’s 50-day moving average is $462.34 and its two-hundred day moving average is $451.98. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The firm has a market capitalization of $183.94 billion, a PE ratio of 28.17, a price-to-earnings-growth ratio of 2.63 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company posted $5.37 earnings per share. The firm’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).